Abstract 78 Table 1
| Endpoints | Early antibody development (n=89) | Late antibody development (n=42) | Log rank p-value | Endpoints* | Early class i antibody development (n=24) | Late class i antibody development (n=3) | Log rank p-value | Endpoints* | Early class ii antibody development (n=55) | Late class ii antibody development (n=36) | Log rank p-value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Subsequent 1 Year Survival | 92.1% | 88.1% | 0.359 | Subsequent 1 Year Survival | 100.0% | 100.0% | 1.000 | Subsequent 1 Year Survival | 87.3% | 86.1% | 0.717 |
| Subsequent 1 Year Freedom from Any-Treated Rejection | 70.8% | 54.8% | 0.030 | Subsequent 1 Year Freedom from Any-Treated Rejection | 87.5% | 66.7% | 0.251 | Subsequent 1 Year Freedom from Any-Treated Rejection | 63.6% | 52.8% | 0.172 |
| Subsequent 1 Year Freedom from Acute Cellular Rejection | 86.5% | 76.2% | 0.083 | Subsequent 1 Year Freedom from Acute Cellular Rejection | 91.7% | 66.7% | 0.099 | Subsequent 1 Year Freedom from Acute Cellular Rejection | 81.8% | 77.8% | 0.485 |
| Subsequent 1 Year Freedom from Antibody-Mediated Rejection | 86.5% | 85.7% | 0.816 | Subsequent 1 Year Freedom from Antibody-Mediated Rejection | 87.5% | 100.0% | 0.531 | Subsequent 1 Year Freedom from Antibody-Mediated Rejection | 87.3% | 83.3% | 0.518 |
| Subsequent 1 Year Freedom from Infection | 36.8% | 21.4% | 0.028 | Subsequent 1 Year Freedom from Infection | 47.8% | 0.0% | 0.182 | Subsequent 1 Year Freedom from Infection | 30.9% | 25.0% | 0.425 |
| Subsequent 1 Year Freedom from NF-MACE | 90.8% | 73.2% | 0.004 | Subsequent 1 Year Freedom from NF-MACE | 100.0% | 66.7% | 0.005 | Subsequent 1 Year Freedom from NF-MACE | 86.8% | 69.4% | 0.023 |
| Subsequent 3 Year Freedom from CAV | 86.5% | 76.2% | 0.012 | Subsequent 3 Year Freedom from CAV | 79.2% | 100.0% | 0.622 | Subsequent 3 Year Freedom from CAV | 90.0% | 75.0% | 0.004 |
*Mixed Class I/Class II Antibodies excluded